Luminex to Buy Back Shares

Nov 17, 2010

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Wednesday that its board of directors has authorized the purchase of up to 1 million shares of the firm's common stock, but not more than $21 million in aggregate purchase price.

Luminex said that the repurchase program will run through November 2011. The purchases will be made from time to time on the open market or through privately negotiated transactions. Luminex currently has 42.3 million shares outstanding.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marine Mammal Gene Loss

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

Cell Count

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

Varied Opinions

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

This Week in PNAS

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Featured White Papers

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Aug

20

Featured Webinar

GenomeWeb/ABRF 2018 Webinar Series: Advances in Single-Cell RNA-Seq: Novel Technologies, Practical Applications

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep

18

Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.

Main menu